MedTrace Logo

Long-term Treatment on BAY77-1931 (Lanthanum Carbonate) to Measure Lanthanum Concentrations in Bone

NCT00767637 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2014-06-20

No results posted yet for this study

Summary

To measure lanthanum concentrations in bone in patients with hyperphosphatemia receiving dialysis

Conditions

  • Hyperphosphatemia
  • Dialysis

Interventions

DRUG

Lanthanum Carbonate (BAY77-1931)

BAY77-1931 750mg, in the morning, day and evening

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-06-30
Primary Completion
2008-10-31
Completion
2008-10-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00767637 on ClinicalTrials.gov